LRI Investments LLC Has $184,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

LRI Investments LLC trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 175 shares of the biopharmaceutical company’s stock after selling 74 shares during the period. LRI Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $184,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rakuten Securities Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $26,000. Sachetta LLC raised its stake in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the period. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. Finally, Family Firm Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $33,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $778.50 on Wednesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20. The company’s 50-day moving average is $871.59 and its 200 day moving average is $1,010.52. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company has a market capitalization of $85.55 billion, a P/E ratio of 19.27, a price-to-earnings-growth ratio of 3.00 and a beta of 0.08.

Wall Street Analyst Weigh In

REGN has been the subject of several research reports. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price for the company. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, Royal Bank of Canada reduced their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.90.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.